African-American renal transplant recipients experience decreased risk of death due to infection: Possible implications for immunosuppressive strategies

Transplantation

Volumn 70, Issue 2, 2000, Pages 375-379

  Meier Kriesche, Herwig Ulf ^a   Ojo, Akinlolu ^a   Magee, John C ^a   Cibrik, Diane M ^a   Hanson, Julie A ^a   Leichtman, Alan B ^a   Kaplan, Bruce ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CAUCASIAN; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEGRO; POSTOPERATIVE INFECTION; PRIORITY JOURNAL;

EID: 0034721066     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200007270-00024     Document Type: Article

References (27)

1. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S, Cho YW, Yuge J. Risk rate and long-term kidney transplant survival. Clin Transplant 1996; XX: 443.
2. Stuart FP, Hill JL, Reckard CR, Buckingham M, Nakamura S: Race as a risk factor in cadaver kidney transplantation. Arch Surg 1979; 114: 416.
3. Garvin PJ, Castaneda M, Codd JE, Mauller K: Recipient race as a risk factor in renal transplantation. Arch Surg 1983; 118: 1441.
4. Barger BO, Hudson SL, Shroyer TW, et al.Influence of race on renal allograft survival in the pre- and postcyclosporine era. Clin Transplant 1987; XX: 217.
5. Yuge J, Cecka JM. The race effect. Clin Transplant 1989; 16: 407.
6. Dawidson IJ, Coorpender L, Fisher D, et al. Impact of race on renal transplant outcome. Transplantation 1990; 49: 63.
7. Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. Clin Transplant 1990; XX: 447.
8. Koyama H, Cecka JM: Race effects. Clin Transplant 1991; XX: 269.
9. Brayman KL, Egidi FM, Naji A, et al. Renal transplantation at the University of Pennsylvania Medical Center: An update of results in the cyclosporine era. Clin Transplant 1992; XX: 215.
10. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts. Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840.
11. Gaston RS, Hudson SL, Deierhoi MH, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103.
12. Cooper TY, Jordan CL, Willimon CM, Land G. Comparison of panel-reactive antibody levels in Caucasian and African American renal transplant candidates. Transplantation 1995; 60: 327.
13. Cosio FG, Dillon JJ, Falkenhain ME, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int 1995; 47: 1136.
14. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships between arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29: 419.
15. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transplant 1995; XX: 379.
16. Ojo AO, Port FK, Held PJ, et al. Inferior outcome of two-haplotype matched renal transplants in blacks: Role of early rejection. Kidney Int 1995; 48: 1592.
17. Gaston RS. Factors affecting renal allograft survival in African Americans. Blood Purif 1996; 14: 327.
18. Ward FE, MacQueen JM. Immunogenetic factors that may contribute to ethnic differences in renal allograft survival. Clin Transplant 1996; 10: 620.
19. Kahan BD, Welsh M, Schoenberg L, et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599.
20. Siegal BR, Greenstein SM. Postrenal transplant compliance from the perspective of African-Americans, Hispanic-Americans, and Anglo-Americans. Adv Ren Replace Ther 1997; 4: 46.
21. Chertow GM, Milford EL. Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther 1997; 4: 40.
22. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405.
23. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997; 64: 1277.
24. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998; 65: 515.
25. Raofi V, Holman DM, Coady N, et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Am J Surg 1999; 177: 299.
26. Schweitzer EJ, Yoon S, Fink J, et al. Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. Transplantation 1998; 65: 242.
27. Meier-Kriesche HU, Friedman G, Jacobs MG, Mulgaoskar S, Vaghela M, Kaplan B. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation 1999; 68: 1496.